

## Childhood pulmonary tuberculosis: A silent threat.

Hao Zhang\*

Department of Pediatrics, Oklahoma State University, Oklahoma, United States

### Introduction

Childhood pulmonary tuberculosis (TB) remains a significant public health concern worldwide, despite considerable progress in the fight against this ancient disease. TB is caused by the bacterium *Mycobacterium tuberculosis* and primarily affects the lungs, leading to a range of respiratory symptoms. While TB can affect individuals of all ages, children are particularly vulnerable due to their developing immune systems and susceptibility to severe complications. In this article, we will delve into the unique challenges of diagnosing and treating pulmonary TB in children, emphasizing the importance of early detection and intervention [1].

Pulmonary TB in children often presents differently than in adults, making it a diagnostic challenge. The symptoms may be subtle or mimic those of common childhood illnesses, such as pneumonia or bronchitis. Cough, fever, and weight loss are common signs, but they can easily be attributed to other causes, delaying proper diagnosis [2].

One of the significant hurdles in diagnosing pediatric TB is the difficulty in obtaining a sputum sample for testing. Young children often cannot produce an adequate sputum sample, and this is further complicated by the lower bacterial load in pediatric cases. Consequently, healthcare providers must rely on other diagnostic methods such as chest X-rays, tuberculin skin tests, and interferon-gamma release assays. These tests, however, are not foolproof, and a definitive diagnosis often requires a combination of clinical judgment and laboratory results. Delayed diagnosis and treatment of childhood pulmonary TB can have severe consequences. The disease can progress, leading to more extensive lung damage and complications. Additionally, an untreated child with TB can potentially transmit the infection to others, further fueling the TB epidemic [3].

Furthermore, the social and psychological impact on children with TB should not be underestimated. Stigma and discrimination can arise within communities, schools, and even among family members. Children with TB may experience isolation, rejection, and emotional distress, which can impede their overall well-being and mental health. Once diagnosed, the treatment of pediatric pulmonary TB can be arduous. Children are typically prescribed a combination of antibiotics for six to nine months, with close monitoring to ensure adherence and address any adverse effects. The lengthy treatment duration can be particularly challenging for children and their families, leading to issues with compliance [4].

Moreover, children may experience side effects from the medications, such as nausea, vomiting, and hepatotoxicity. Healthcare providers must carefully balance the need for effective treatment with minimizing these adverse effects. Childhood pulmonary tuberculosis is a hidden threat that requires a vigilant and compassionate response from the global community. Diagnosing TB in children can be challenging due to atypical symptoms and difficulties in obtaining sputum samples. Delayed diagnosis not only leads to more severe health consequences but also contributes to the spread of the disease. Additionally, the social and psychological impact on affected children can be profound. Efforts to combat childhood TB should focus on early detection, improved diagnostic tools, and strategies to enhance treatment adherence. Raising awareness about the disease and reducing the associated stigma are also crucial components of a comprehensive approach to tackling this global health issue [5].

### Conclusion

Childhood pulmonary tuberculosis is a complex and often overlooked problem. By addressing the unique challenges of diagnosing and treating TB in children, we can work toward a future where no child's life is disrupted or endangered by this preventable and treatable disease. It is our collective responsibility to ensure that children with TB receive the care and support they need to lead healthy, productive lives.

### References

1. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. *The Lancet*. 2013;381(9871):1021-8.
2. Harris RC, Dodd PJ, White RG. The potential impact of BCG vaccine supply shortages on global paediatric tuberculosis mortality. *BMC Med*. 2016;14:1-7.
3. van der Heijden YF, Heerman WJ, McFadden S, et al. Missed opportunities for tuberculosis screening in primary care. *J Pediatr*. 2015;166(5):1240-5.
4. Srivastava S, Deshpande D, Pasipanodya JG, et al. A combination regimen design program based on pharmacodynamic target setting for childhood tuberculosis: design rules for the playground. *Clin Infect Dis*. 2016;63(suppl\_3):S75-9.
5. Nachman S, Ahmed A, Amanullah F, et al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. *Lancet Infect Dis*. 2015;15(6):711-20.

\*Correspondence to: Hao Zhang, Department of Pediatrics, Oklahoma State University, Oklahoma, United States, E-mail: haoz@hotmail.com

Received: 26-Sept-2023, Manuscript No. AAJCAH-23-115975; Editor assigned: 28-Sept-2023, Pre QC No. AAJCAH-23-115975(PQ); Reviewed: 11-Oct-2023, QC No. AAJCAH-23-115975; Revised: 16-Oct-2023, Manuscript No. AAJCAH-23-115975(R); Published: 23-Oct-2023, DOI: 10.35841/aaajcah-7.5.166